FDA Regs On Experimental Drug Access May Be Loosened After Court Loss
Executive Summary
FDA's ongoing development of rules for expanded access programs will likely take a broader approach after the agency's current standards were questioned by an appeals court
You may also be interested in...
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice
FDA Can Expand Access To Experimental Drugs, Without Compromising Trials
FDA would be able to maintain the integrity of rigorous clinical trials and permit increased access to experimental drugs through the use of better science, according to former FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb
Outcome Of Abigail Alliance Case May Be Moot Due To Marketplace Issues
Regardless of whether a federal appeals court determines that patients have a fundamental right to experimental therapy, it appears a host of potential problems in the marketplace will stymie increased access to such therapies in practice